Rejuvenate aged adaptive immunity with bioengineered thymus organoids

用生物工程胸腺类器官恢复衰老的适应性免疫力

• 批准号: 9307727
• 负责人: YONG FAN
• 金额: $ 18.95万
• 依托单位: ALLEGHENY-SINGER RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9307727
• 关键词: 3-Dimensional; Adaptive Immune System; Age; Age-Years; Aging; Allogenic; Antigens; Architecture; Atrophic; Autoimmune Diseases; Biomedical Engineering; Birth; Cell Compartmentation; Cell Differentiation process; Cells; Cellularity; Chronic Disease; Complement; Cues; Cultured Cells; Data; Defect; Developed Countries; Developing Countries; Development; Elderly; Embryo; Environmental Risk Factor; Epithelial; Epithelium; Explosion; Extracellular Matrix; Fibroblasts; Generations; Goals; Healthcare; Homing; Human; Immune; Immune System Diseases; Immune System and Related Disorders; Immune response; Immune system; Immunization; In Vitro; Individual; Infection; Influenza; Laboratories; Life Expectancy; Lymphocyte; Malignant Neoplasms; Medical; Modern Medicine; Molecular; Mus; Natural regeneration; Nude Mice; Organ; Organoids; Output; Peripheral; Pharmacotherapy; Phenotype; Population; Predisposition; Property; Protocols documentation; Publishing; Quality of life; Refractory; Regenerative Medicine; Rejuvenation; Research Project Grants; Research Proposals; Signal Transduction; Skin graft; Source; Stem cells; T memory cell; T-Cell Development; T-Lymphocyte; Techniques; Technology; Therapeutic; Thymic epithelial cell; Thymus Gland; Tissues; Translating; Transplantation; Vaccination; adaptive immune response; adaptive immunity; age related; aged; aging population; base; cost; cytokine; embryonic stem cell; human embryonic stem cell; immune function; immunosenescence; improved; in vivo; innovation; irradiation; next generation sequencing; novel; pathogen; postnatal; pre-clinical research; progenitor; response; scaffold; skin allograft; stem cell differentiation; success; transdifferentiation; young adult

ABSTRACT One of the most prominent consequences of aging is the decline of immune function. Quite often, elderly individuals do not respond efficiently to novel or previously encountered antigens. This is exemplified by increased vulnerability of individuals 70 years of age and older to influenza and other infectious pathogens. The situation is exacerbated further by their refractory to protective vaccination. Thanks to the advances of modern medicine, life expectancy in developed countries has increased dramatically in the past century. Developing therapeutics to rejuvenate aged immune system will not only have tremendous impact on the quality of living of the fast growing aged population, but also help to stop the explosion of the age-related medical cost. Thymus involution, a condition manifested as progressive regression in thymic size and cellularity, is the one of the leading causes for age-associated immune dysfunction. While numerous efforts have been made to modulate/rejuvenate thymic function, manipulating the thymus, either in vitro or in vivo, proves to be difficult. The major challenge is to reproduce its unique extracellular matrix microenvironment that is critical for the survival and function of thymic epithelial cells (TECs), the predominant population within thymic stroma that are critical for both the success of T-cell development and maintaining the integrity of the thymus microenvironment. TECs cultured in traditional 2-D culture rapidly lose their molecular properties and fail to thrive. The preclinical research proposal proposes an innovative approach to rejuvenate the aged thymus. The project will take advantage of a novel thymus bioengineering technique, with which functional thymus organoids can be constructed de novo with isolated TECs. When transplanted into athymic mice, the bioengineered thymus organoids can support the development of a diverse, self-tolerant T-cell population in the hosts. The primary goal of the proposed project is to demonstrate the proof-of-concept that bioengineered thymus organoids constructed with TECs of younger donors can effectively rejuvenate adaptive immunity in aged mice (Aim 1). One foreseeable obstacle of the thymus bioengineering approach is the scarcity of TECs due to the rapid contraction of the postnatal TEC compartment, which occurs as early as 4-weeks after birth in mouse and 1 year in human. The proposal will explore the possibility of using human embryonic stem cells (hESCs) as an alternative source of TECs for therapeutics. The microenvironment of the bioengineered thymus scaffolds can provide both the extracellular matrix support and the signaling cues that might induce the differentiation of hESCs to TECs. Aim 2 of the proposal will demonstrate that the bioengineered thymus organoids constructed from TECs derived from hESCs can rejuvenate the adaptive immune system in aged mice. The long-term goal of the research project is to translate the thymus bioengineering technique to rejuvenate adaptive immunity in elders and to treat age-related immune dysfunction.

摘要 衰老最突出的后果之一是免疫功能下降。很多时候， 老年人对新的或以前遇到的抗原不能有效应答。这方面的例子有： 70岁及以上的人更容易感染流感和其他传染性病原体。 这种情况由于他们对保护性疫苗接种的抵抗而进一步恶化。多亏了 从现代医学的角度来看，发达国家的预期寿命在过去的世纪里有了显著的提高。 开发治疗方法来恢复衰老的免疫系统不仅会对免疫系统产生巨大影响， 快速增长的老年人口的生活质量，也有助于阻止与年龄有关的爆炸 医疗费用。 胸腺退化是一种表现为胸腺大小和细胞结构进行性退化的疾病， 这是导致年龄相关免疫功能障碍的主要原因之一。虽然已经做出了许多努力， 为了调节/恢复胸腺功能，无论是在体外还是在体内， 难主要的挑战是复制其独特的细胞外基质微环境，这对 胸腺上皮细胞（TEC）的存活和功能，TEC是胸腺基质中的主要群体， 对于T细胞发育的成功和维持胸腺的完整性都至关重要 微环境在传统的二维培养中培养的TEC迅速失去其分子特性， 茁壮成长临床前研究提案提出了一种创新的方法来恢复衰老的胸腺。的 项目将利用一种新的胸腺生物工程技术， 类器官可以用分离的TEC从头构建。当移植到无胸腺小鼠体内时， 生物工程化的胸腺类器官可以支持多种多样的，自我耐受的T细胞群的发展， 主持人。拟议项目的主要目标是证明生物工程的概念验证 用年轻供体的TEC构建的胸腺类器官可以有效地恢复适应性免疫， 老年小鼠（Aim 1）。胸腺生物工程方法的一个可预见的障碍是TEC的稀缺 由于出生后TEC隔室的快速收缩，其早在出生后4周就发生， 小鼠和人类1年。该提案将探索使用人类胚胎干细胞的可能性 将人胚胎干细胞（hESC）作为用于治疗的TEC的替代来源。生物工程的微环境 胸腺支架可以提供细胞外基质支持和可能诱导细胞凋亡的信号线索。 hESC向TEC的分化。该提案的目标2将证明生物工程胸腺 由来源于hESC的TEC构建的类器官可以使老年人的适应性免疫系统恢复活力。 小鼠该研究项目的长期目标是将胸腺生物工程技术转化为 恢复老年人的适应性免疫力，并治疗与年龄相关的免疫功能障碍。